Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials. Issue 9 (September 2021)

• Record Type: Journal Article
• Authors: Fallah, Jaleh; Zhang, Lijun; Amatya, Anup; Gong, Yutao; King-Kallimanis, Bellinda; Bhatnagar, Vishal; Weinstock, Chana; Suzman, Daniel L; Agrawal, Sundeep; Chang, Elaine; Anscher, Mitchell S; Chi, Dow-Chung; Xu, James X; Brewer, Jamie R; Brave, Michael H; Hadadi, Mehrnoosh; Theoret, Marc R; Kluetz, Paul G; Goldberg, Kirsten B; Ibrahim, Amna; Tang, Shenghui; Pazdur, Richard; Beaver, Julia A; Amiri-Kordestani, Laleh; Singh, Harpreet
• Is Part Of: Lancet oncology. Volume 22:Issue 9(2021)
• Page Start: 1230
• Page End: 1239
• Publication Date: 2021-09
• Subjects: Oncology -- Periodicals; Neoplasms -- Periodicals; Cancérologie -- Périodiques; Oncologie; Oncology; Periodicals; Electronic journals; 616.994005
• DOI: 10.1016/S1470-2045(21)00334-X
• Languages: English
• ISSNs: 1470-2045

Abstract

Summary: Background: Little is known about the benefit–risk profile of second-generation androgen receptor inhibitors in older men with non-metastatic castration-resistant prostate cancer. We aimed to examine the efficacy and safety of second-generation androgen receptor inhibitors in men aged 80 years or older with non-metastatic castration-resistant prostate cancer. Methods: We searched for all randomised controlled clinical trials evaluating second-generation androgen receptor inhibitors in patients with non-metastatic castration-resistant prostate cancer submitted to the US Food and Drug Administration before Aug 15, 2020, and pooled data from three trials that met the selection criteria. All three trials enrolled patients who were aged 18 years or older with an Eastern Cooperative Oncology Group performance status of 0–1, castration-resistant prostate cancer, prostate-specific antigen (PSA) 2·0 μg/L or greater, PSA doubling time of 10 months or less, and no evidence of distant metastatic disease on conventional imaging per the investigator's assessment at the time of screening. All patients had histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small-cell features. All patients who were randomly assigned to androgen receptor inhibitor or placebo groups in these trials were considered assessable and were included in this pooled analysis. We evaluated the effect of age on metastasis-free survival and overall survival across age groups (<80 years vs ≥80 years) in the intention-to-treat population. Safety analyses were done in patients who received at least one dose of study treatment. Findings: Between Oct 14, 2013, and March 9, 2018, 4117 patients were assigned to androgen receptor inhibitor (apalutamide, enzalutamide, or daralutamide; n=2694) or placebo (n=1423) across three randomised trials. The median follow-up duration for metastasis-free survival was 18 months (IQR 11–26) and for overall survival was 44 months (32–55). In patients aged 80 years or older (n=1023), the estimated median metastasis-free survival was 40 months (95% CI 36–41) in the androgen receptor inhibitor groups and 22 months (18–29) in the placebo groups (adjusted hazard ratio [HR] 0·37 [95% CI 0·28–0·47]), and the median overall survival was 54 months (50–61) versus 49 months (43–58), respectively (adjusted HR 0·79 [0·64–0·98]). In patients younger than 80 years of age (n=3094), the estimated median metastasis-free survival was 41 months (95% CI 36–not estimable [NE]) in the androgen receptor inhibitor groups and 16 months (15–18) in the placebo groups (adjusted HR 0·31 [95% CI 0·27–0·35]), and the median overall survival was 74 months (74–NE) versus 61 months (56–NE), respectively (adjusted HR 0·69 [0·60–0·80]). In patients aged 80 years or older, grade 3 or worse adverse events were reported in 371 (55%) of 672 patients in the androgen receptor inhibitor groups and 140 (41%) of 344 patients in the placebo groups, compared with 878 (44%) of 2015 patients in the androgen receptor inhibitor groups and 321 (30%) of 1073 patients in the placebo groups among patients younger than 80 years. The most common grade 3–4 adverse events were hypertension (168 [8%] of 2015 patients aged <80 years and 51 [8%] of 672 patients aged ≥80 years in the androgen receptor inhibitor groups vs 53 [5%] of 1073 patients aged <80 years and 22 [6%] of 344 patients aged ≥80 years in the placebo groups) and fracture (61 [3%] and 36 [5%] in the androgen receptor inhibitor groups vs 15 [1%] and 11 [3%] in the placebo groups). Interpretation: The findings of this pooled analysis support the use of androgen receptor inhibitors in older men with non-metastatic castration-resistant prostate cancer. Incorporating geriatric assessment tools in the care of older adults with non-metastatic castration-resistant prostate cancer might help clinicians to offer individualised treatment to each patient. Funding: None.